The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; none of the 40 sources its claims cite is checked for support yet.
Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo
Open accessAbstract
The combination of Cas9, guide RNA and repair template DNA can induce precise gene editing and the correction of genetic diseases in adult mammals. However, clinical implementation of this technology requires safe and effective delivery of all of these components into the nuclei of the target tissue. Here, we combine lipid nanoparticle-mediated delivery of Cas9 mRNA with adeno-associated viruses encoding a sgRNA and a repair template to induce repair of a disease gene in adult animals. We applied our delivery strategy to a mouse model of human hereditary tyrosinemia and show that the treatment generated fumarylacetoacetate hydrolase (Fah)-positive hepatocytes by correcting the causative Fah-splicing mutation. Treatment rescued disease symptoms such as weight loss and liver damage. The efficiency of correction was >6% of hepatocytes after a single application, suggesting potential utility of Cas9-based therapeutic genome editing for a range of diseases.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This study combined lipid nanoparticle delivery of Cas9 mRNA with AAV-delivered sgRNA and an HDR template to correct the Fah mutation in a mouse model of hereditary tyrosinemia type I. A single treatment corrected >6% of hepatocytes, restored Fah splicing, and rescued weight loss and liver damage.
Key findings
- In Fahmut/mut mice, combined nano.Cas9 + AAV-HDR treatment yielded 6.2% ± 1.0% Fah-positive hepatocytes by immunohistochemistry after a single application (n = 4 mice), with correction correlating with nano.Cas9 and AAV-HDR dose.
- Treated mice had 9.5% restored FAH mRNA without selection, 24.1% average indels at the sgRNA target region, and 0.81% ± 0.08% corrected “G-CC” sequence in total liver DNA by deep sequencing.
- Treatment completely prevented body weight loss after NTBC withdrawal, all nano.Cas9 + AAV-HDR mice survived 30 days, and serum AST, ALT, and bilirubin indicated substantially reduced liver damage compared with controls.
- Off-target editing was low at assayed sites: <0.3% indels at three top predicted off-target sites, and in vivo OT1/GOT sites were not substantially higher than background (P > 0.05); transient mRNA Cas9 also reduced off-target editing versus long-term lentiviral Cas9 in cells.
Methods
- Fahmut/mut mice (8–10 weeks old, male and female) were injected via tail vein with AAV2/8-HDR (6 × 10^11 or 1.2 × 10^12 genome copies) and nano.Cas9 (1 or 2 mg/kg); in the efficacy experiment, AAV-HDR was given at day −14, nano.Cas9 at day −7, and NTBC water was withdrawn at day 0.
- Cas9 mRNA was chemically modified and formulated with C12-200, cholesterol, C14PEG2000, DOPE, and arachidonic acid in lipid nanoparticles; AAV-HDR encoded U6-sgRNA and a 1.7-kb HDR template designed to correct the mutant “A” to wild-type “G” and introduce a “CC” PAM motif.
- Analyses included liver immunohistochemistry, serum biomarkers, qRT-PCR, Sanger sequencing, Illumina deep sequencing, GUIDE-Seq in Hepa1-6 cells, and statistics by Student’s t-tests and one-way ANOVA with Tukey post-test.
Limitations
- Stated: non-viral delivery of DNA into the nucleus in vivo with high efficiency and low toxicity remains difficult, and further improvement of HDR efficacy may require optimizing HDR template design and inhibiting the NHEJ pathway.
- Stated: the stringent “G-CC” pattern counting may underestimate HDR events, and an alternative explanation for the observed data is partial gene conversion; off-target analysis was limited to predicted and assayed sites.
- Evident from the text: efficacy was shown only in the Fahmut/mut mouse model, with small group sizes (n = 3–4 mice) and 30-day follow-up, so long-term durability, AAV immunogenicity, and human translation are not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 40 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The analysis of deep sequencing data confirmed a corrected “G-CC” pattern at the Fah locus in 0.81% ± 0.08% of the total liver DNA, in contrast to the AAV-HDR alone group, which contained no detectable “G-CC” sequences (Fig. 3g).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here we report that systemic delivery of Cas9 mRNA by lipid nanoparticles and sgRNA/HDR template by AAV can efficiently cure Fahmut/mut mice.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed insertional or deletional mutations (indels) surrounding the Cas9 cleavage site (Fig. 1c–e and Supplementary Table 3).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The number of Fah-positive hepatocytes correlated with the dose of nano.Cas9 and AAV-HDR (Fig. 3c).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“To determine whether lipid nanoparticles can deliver Cas9 mRNA, nano.Cas9 (1 mg/kg or 2 mg/kg) was injected intravenously, and Cas9 protein in total liver lysates was detected by immunoblot (Supplementary Fig. 2d).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed a number of GUIDE-Seq oligonucleotide integration sites within the genome (Supplementary Table 7) but only the Fah target site and one other site (OT1, which is also the computationally predicted off-target site with the fewest mismatches in the genome; Supplementary Fig. 7) passed our stringent criteria for potential nuclease cleavage sites (Supplementary Table 8).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, at least for Ctnnb1, the all-viral Cas9 delivery did not significantly increase the HDR rate compared to mRNA delivery.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 30 d after NTBC water withdrawal, serum biomarkers (AST, ALT and bilirubin) indicated that liver damage was substantially reduced in nano.Cas9 + AAV-HDR–treated mice compared to control mice (Fig. 2c).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed an average of 24.1% indels at predicted sgRNA target region within nano.Cas9 (2 mg/kg) + AAV-HDR group (1.2 × 1012) (Fig. 3f and Supplementary Table 5) (n = 4 mice).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All the mice in the nano.Cas9 + AAV-HDR group survived 30 d after NTBC withdrawal.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 15
- It may state two separate claims as one. 28
- The quote only partly states this claim. 1
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean particle diameter of nano.Cas9 is about 120 nm as determined by dynamic light scattering (Supplementary Fig. 1c).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared to indels at the on-target Fah site (Fig. 3f), <0.3% indels were detected at the assayed off-target sites in nano.Cas9 + AAV-HDR–treated mice, and these numbers were comparable with AAV-HDR–treated control mice (Supplementary Fig. 7 and Supplementary Table 6), indicating that Cas9 mRNA delivery has minimal off-target effects at assayed sites for Fah sgRNA.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“OT1 and several other assayed sites had modest indel rates, and none of these sites were substantially higher than the background indel rate in untreated livers (P > 0.05; Supplementary Fig. 8b and Supplementary Table 9).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed ∼24% indels and ∼1.2% beta-Catenin–positive hepatocytes in vivo (Supplementary Fig. 6).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed a clear band in livers of nano.Cas9 + AAV-HDR–treated animals, but not in control animals (Supplementary Fig. 5b). We sequenced the band and identified that the corrected sequence (“G-CC” pattern) is integrated (Supplementary Fig. 5c).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These additional sites did not meet our peak calling criteria, but we detected 2.4% and 1.8% indels at OT1 in two replicates (Supplementary Fig. 8a and Supplementary Table 9), consistent with OT1 being a Cas9:sgFah off-target site in transformed cells in vitro.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Cas9 mRNA was present in the liver at 4 h and 14 h but was significantly diminished at 24 h (P < 0.05), consistent with transient expression (Supplementary Fig. 2e).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found sgRNA was already expressed at day 3, but its levels were more than tenfold higher at day 7 and day 14.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The efficiency of correction was >6% of hepatocytes after a single application, suggesting potential utility of Cas9-based therapeutic genome editing for a range of diseases.”
- Also stated in: § Abstract · plain
“Up to 6.2% ± 1.0% hepatocytes stained positive for the Fah protein by immunohistochemistry in nano.Cas9 plus AAV-HDR–treated animals (Fig. 3b,c; n = 4 mice; see Supplementary Table 4 for percentage of Fah-positive cells, age and gender of each mouse).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The particle size of nano.Cas9 was the same on day 0, 7, 11 and 18 (Supplementary Fig. 1d,e), indicating these particles are stable for at least 18 d in PBS.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“β-gal protein was detected in the mouse liver by immunoblot at 14 h after administration of a single dose (1 mg/kg or 2 mg/kg), and the amount of protein expressed correlated with the dose of mRNA (Supplementary Fig. 2b).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most indels are frameshift (e.g., 1 nt and 2 nt) mutations (Fig. 1e), which potentially cause loss of function of the GFP reporter.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Systemic delivery of Cas9 mRNA by lipid nanoparticles, and sgRNA/HDR template by AAV, corrected a Fah mutation and restored Fah splicing in more than 6% of hepatocytes in the adult mouse liver, an order of magnitude improvement over that previously generated using high-pressure injection of DNA16.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [16] Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551–553 (2014). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This treatment is well-tolerated in mice and fully rescued body weight loss and liver damage in tyrosinemia mice.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The majority of the cells in liver sections stained positive in a β-gal activity assay (Supplementary Fig. 2c), indicating systemic delivery of mRNA to most of the cells in the mouse liver.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In HTI patients, mutation of fumarylacetoacetate hydrolase (FAH), the last enzyme catalyzing the tyrosine catabolic pathway, leads to accumulation of toxic metabolites and severe liver damage8.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [8] Paulk, N.K. et al. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 51, 1200–1208 (2010). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The Fahmut/mut mouse model6,8 is caused by a G→A point mutation in the last nucleotide of exon 8. This causes skipping of exon 8 and truncated Fah mRNA.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [6] Aponte, J.L. et al. Point mutations in the murine fumarylacetoacetate hydrolase gene: animal models for the human genetic disorder hereditary tyrosinemia type 1. Proc. Natl. Acad. Sci. USA 98, 641–645 (2001). source
- Not checked yetcites [8] Paulk, N.K. et al. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 51, 1200–1208 (2010). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An alternative approach is the non-viral delivery of Cas9 mRNA, which would allow for short-term expression and, eventually, complete removal of the nuclease from the body.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“However, all of these delivery studies have reported gene knockout rather than gene repair, a less efficient process requiring a DNA repair template15.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [15] Chu, V.T., Weber, T. & Wefers, B. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 33, 543–548 (2015). source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Cas9:sgRNA recognizes the protospacer-adjacent motif (PAM) sequence and a complementary 20-nucleotide genomic sequence and induces double-strand DNA breaks, which are repaired by error-prone nonhomologous end-joining (NHEJ) or precise homology-directed repair (HDR)2,5.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [2] Doudna, J.A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014). source
- Not checked yetcites [5] Sander, J.D. & Joung, J.K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32, 347–355 (2014). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“Recently, a smaller form of Cas9 was developed, and shown capable of packing and delivery with sgRNA by AAV in vivo12.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [12] Ran, F.A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015). source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Lipid and lipid-like formulations have shown great promise as delivery agents for siRNA in a range of species, including humans19.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [19] Yin, H. et al. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541–555 (2014). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Nevertheless, hydrodynamic injection yielded a low correction rate of 0.4% of hepatocytes, and this method has been tested in only one human clinical trial17.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [16] Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551–553 (2014). source
- Not checked yetcites [17] Khorsandi, S.E. et al. Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human. Cancer Gene Ther. 15, 225–230 (2008). source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“However, AAV has a loading capacity size of approximately 4.7 kb, and the most commonly used form of Cas9 from Streptococcus pyogenes is difficult to fit in typical AAV constructs with efficient promoters13.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [13] Swiech, L. et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 33, 102–106 (2015). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“These mice can be treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), an inhibitor of an enzyme upstream of Fah, to prevent toxin accumulation in hepatocytes8.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [8] Paulk, N.K. et al. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 51, 1200–1208 (2010). source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“To express sgRNA, we treated animals with up to 1.2 × 1012 AAV genome copies/mouse, a standard dose described in the literature28.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [28] Barzel, A. et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature 517, 360–364 (2015). source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This allowed for short-term expression of the Cas9 nuclease, which provided efficient on-target genome editing, while potentially reducing off-target editing (Fig. 1h).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A smaller form of Cas9 (Staphylococcus aureus Cas9), which fits into AAV vectors, has been recently used to knockout genes by NHEJ in the mouse liver. More than 40% indel formations in Pcsk9 locus was reported12.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [12] Ran, F.A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015). source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All animal experiments were performed under the guideline of the MIT Animal Care and Use Committee.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Online Methods > Animal experiments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This estimation is consistent with the 0.81% corrected “G-CC” sequence pattern observed by deep sequencing in treated liver samples (Fig. 3g).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
In the paper
“A recent study demonstrated that the chemical modification of sgRNA improved gene editing in vitro when co-delivered with Cas9 mRNA32.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [32] Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985–989 (2015). source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“A key feature of our system is the transient expression of the nuclease Cas9, through delivery of mRNA. This allowed for sufficient exposure to the nuclease for gene repair and reduced concerns associated with long-term nuclease exposure34.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [34] Wu, X. et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat. Biotechnol. 32, 670–676 (2014). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The CRISPR systems have a number of potential advantages over ZFNs, most importantly their flexibility and ease in adjusting target site4.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [4] Mali, P., Esvelt, K.M. & Church, G.M. Cas9 as a versatile tool for engineering biology. Nat. Methods 10, 957–963 (2013). source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“However, correction of 6% of hepatocytes following a single round of treatment without selection suggests that this approach may be suitable for the treatment of a range of metabolic liver diseases and hemophilia, where restoration of 3–7% normal functional protein can be therapeutic39.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [39] Cox, D.B., Platt, R.J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121–131 (2015). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“An alternative explanation for this observation is partial gene conversion in spite of “G” and “CC” single-nucleotide polymorphisms equidistant to the Cas9 cutting site.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [36] Elliott, B., Richardson, C., Winderbaum, J., Nickoloff, J.A. & Jasin, M. Gene conversion tracts from double-strand break repair in mammalian cells. Mol. Cell. Biol. 18, 93–101 (1998). source
- Not checked yetcites [37] Goldberg, A.D. et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 140, 678–691 (2010). source
- Not checked yetcites [38] Findlay, G.M., Boyle, E.A., Hause, R.J., Klein, J.C. & Shendure, J. Saturation editing of genomic regions by multiplex homology-directed repair. Nature 513, 120–123 (2014). source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Previous work has reported on the use of zinc finger nucleases (ZFNs) for in vivo gene correction31,33.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [31] Mahiny, A.J. et al. In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. Nat. Biotechnol. 33, 584–586 (2015). source
- Not checked yetcites [33] Li, H. et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217–221 (2011). source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It is possible that our stringent “G-CC” pattern counting underestimated the HDR event.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although NHEJ has been reported using AAV-mediated Cas9 delivery, HDR using viral delivery in vivo has not been reported.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Cells were tested by MIT core facility for mycoplasma contamination by an ELISA-based assay, and confirmed negative.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Online Methods > Cell culture, off-target analysis and Illumina sequencing
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“For example, less than 10% indels at the Apob locus in the mouse liver was reported in the same study12.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [12] Ran, F.A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015). source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
Clinical implementation of CRISPR genome editing requires safe and effective delivery of all components into the nuclei of the target tissue.
“However, clinical implementation of this technology requires safe and effective delivery of all of these components into the nuclei of the target tissue.”
The paper relies on this without support.
Improvements to CRISPR delivery methods and HDR efficiency are required for therapeutic application of genome editing for disease gene correction.
“However, improvements to CRISPR delivery methods and HDR efficiency are required for therapeutic application of genome editing for disease gene correction.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“If delivering Cas9 mRNA and sgRNA, this method is functionally like microinjection in result (Yin et al., 2016).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Yin et al., 2016
Experimental — accuracy not yet measuredIn the citing paper
“Gene-editing components can be delivered by lipid nanoparticle–mRNA formulations to treat genetic diseases, including HTI92,238, hypercholesterolaemia81,96,105,239, lipoprotein metabolism disorders85 and transthyretin amyloidosis239,240, which has been demonstrated in preclinical studies.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [92]
In the citing paper
“We and others recently reported that CRISPR can correct this Fah mutation through HDR16–18 or allelic exchange19.”
From Adenine base editing in an adult mouse model of tyrosinaemia (2019) · cites this paper as [16]
In the citing paper
“Using the standard Guide-seq protocol, we detected only the Fah target site and one off-target site (defined as Guide-seq off-target site 1, or GOT1) (Supplementary Data Set 1).”
From Adenine base editing in an adult mouse model of tyrosinaemia (2019) · cites this paper as [16]
In the citing paper
“After a single treatment, the FAH expression in more than 6% of hepatocytes was repaired and the symptoms of hepatic damage were prevented in the following 30 days.”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [141]
In the citing paper
“Yin et al. combined lipid nanoparticle-mediated delivery of Cas9 mRNA with AAV encoding sgRNAs and donor templates to repair FAH gene in a mouse model of human hereditary tyrosinemia. The efficiency of correction was >6% of hepatocytes after a single application and the treatment rescued disease symptoms such as weight loss and liver damage [112].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [112]
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationCRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696
Organoid Models and Applications in Biomedical Research
Xinaris, C., Brizi, V., & Remuzzi, G. (2015) · The Nephron journals/Nephron journals · doi:10.1159/000433566 · Cited by 3,519
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Self-citationIn vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 874
Holmgaard, A. B., Askou, A. L., Jensen, E. G., Alsing, S., Bak, R. O., Mikkelsen, J. G., & Corydon, T. J. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.032 · Cited by 36
Advances in CRISPR Delivery Methods: Perspectives and Challenges
Demirci, S., Essawi, K., Germino-Watnick, P., Liu, X., Hakami, W., & Tisdale, J. F. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0051 · Cited by 37
Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems
Wang, M., Liu, H., Huang, J., Cai, T., Xu, Z. P., & Zhang, L. L. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03433-8 · Cited by 37
Heat-Triggered Remote Control of CRISPR-dCas9 for Tunable Transcriptional Modulation
Gamboa, L., Phung, E. V., Li, H., Meyers, J. P., Hart, A. C., Miller, I. C., & Kwong, G. A. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.9b01005 · Cited by 36
Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy
Aghamiri, S., Talaei, S., Roshanzamiri, S., Zandsalimi, F., Fazeli, E., Aliyu, M., Avarvand, O. K., Ebrahimi, Z., Keshavarz‐Fathi, M., & Ghanbarian, H. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1747429 · Cited by 37
Yin, H., Zhou, B., Dong, C., Zhang, Y., Yu, J., Pu, Y., Feng, W., Sun, L., Hu, H., Chen, Y., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107093 · Cited by 36
Self-citationmRNA and gene editing: Late breaking therapies in liver diseases
Zabaleta, N., Torella, L., Weber, N. D., & González‐Aseguinolaza, G. (2022) · Hepatology · doi:10.1002/hep.32441 · Cited by 39
Lee, B. H., Gries, K., Valimukhametova, A. R., McKinney, R. L., González-Rodríguez, R., Topkiran, U. C., Coffer, J. L., Akkaraju, G. R., & Naumov, A. V. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202305506 · Cited by 35
Raigani, M., Eftekhari, Z., Adeli, A., & Kazemi‐Lomedasht, F. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102666 · Cited by 36
Cell-penetrating peptides and their utility in genome function modifications (Review)
Gagat, M., Zielińska, W., & Grzanka, A. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3172 · Cited by 36
Genetic-Based Approaches to Inherited Metabolic Liver Diseases
Zabaleta, N., Hommel, M., Salas, D., & González‐Aseguinolaza, G. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.140 · Cited by 35
mRNA delivery via non-viral carriers for biomedical applications
Shuai, Q., Zhu, F., Zhao, M., & Yan, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121020 · Cited by 35
Gu, C., Xiao, L., Shang, J., Xu, X., He, L., & Xiang, Y. (2021) · Chemical Science · doi:10.1039/d1sc01194d · Cited by 34
The Impact of CRISPR-Cas System on Antiviral Therapy
Bayat, H., Naderi, F., Khan, A. H., Memarnejadian, A., & Rahimpour, A. (2018) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2018.067 · Cited by 34
A Polymeric Nanoparticle Formulation for Targeted mRNA Delivery to Fibroblasts
Rodrigues, A. F., Rebelo, C., Simões, S. M. N., Paulo, C., Pinho, S. L. C., Francisco, V., & Ferreira, L. (2022) · Advanced Science · doi:10.1002/advs.202205475 · Cited by 33
Shakirova, A. I., Karpov, T. E., Komarova, Y., & Lepik, K. V. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1068637 · Cited by 33
Allemailem, K. S., Almatroudi, A., Rahmani, A. H., Alrumaihi, F., Alradhi, A. E., Al-Subaiyel, A., Algahtani, M., Almousa, R. M., Mahzari, A., Sindi, A. A. A., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s455574 · Cited by 36
Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy
Abaza, T., Mohamed, E., & Zaky, M. Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02939-3 · Cited by 35
Synthetic Vehicles for Encapsulation and Delivery of CRISPR/Cas9 Gene Editing Machinery
Carboni, V., Maaliki, C., Alyami, M., Alsaiari, S. K., & Khashab, N. M. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800085 · Cited by 34
Niu, G., Jin, Z., Zhang, C., He, D., Gao, X., Zou, C., Zhang, W., Ding, J., Das, B. C., Severinov, K., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102897 · Cited by 34
Zhang, W., Liu, Y., Chin, J. M., & Phua, K. K. L. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.011 · Cited by 33
mRNA-based modalities for infectious disease management
Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X., & Huang, Y. (2022) · Nano Research · doi:10.1007/s12274-022-4627-5 · Cited by 35
Ling, K., Dou, Y., Yang, N., Deng, L., Wang, Y., Li, Y., Yang, L., Chen, C., Jiang, L., Deng, Q., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.007 · Cited by 34
Self-citationCRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia
Chadwick, A. C., & Musunuru, K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309326 · Cited by 33
Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D., Grindel, B. I., Saxena, S., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20065-8 · Cited by 32
CircRNA knockdown based on antisense strategies
Aquino‐Jarquín, G. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104066 · Cited by 33
Excision of Nucleopolyhedrovirus Form Transgenic Silkworm Using the CRISPR/Cas9 System
Dong, Z., Dong, F., Yu, X., Huang, L., Jiang, Y., Hu, Z., Chen, P., Lu, C., & Pan, M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00209 · Cited by 32
CRISPR/Cas9 Genome Editing to Disable the Latent HIV-1 Provirus
Panfil, A. R., London, J. A., Green, P. L., & Yoder, K. E. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03107 · Cited by 34
VanLith, C. J., Guthman, R. M., Nicolas, C. T., Allen, K. L., Liu, Y., Chilton, J. A., Tritz, Z. P., Nyberg, S. L., Kaiser, R. A., Lillegard, J. B., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1315 · Cited by 32
Using CRISPR/Cas9 to model human liver disease
Alves‐Bezerra, M., Furey, N., Johnson, C. G., & Bissig, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.09.002 · Cited by 32
Efficient in vivo editing of OTC-deficient patient-derived primary human hepatocytes
Ginn, S. L., Amaya, A. K., Liao, S. H. Y., Zhu, E., Cunningham, S. C., Lee, M., Hallwirth, C. V., Logan, G. J., Tay, S. S., Cesare, A. J., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.100065 · Cited by 32
Yin, S., Ma, L., Shao, T., Zhang, M., Guan, Y., Wang, L., Hu, Y., Chen, X., Han, H., Shen, N., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1744-6 · Cited by 33
Ghani, M. W., Iqbal, A., Ghani, H., Bibi, S., Wang, Z., & Pei, R. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02610d · Cited by 32
Biomaterial-Based CRISPR/Cas9 Delivery Systems for Tumor Treatment
Li, M., Chen, F., Yang, Q., Tang, Q., Xiao, Z., Tong, X., Zhang, Y., Lei, L., & Li, S. (2024) · Biomaterials Research · doi:10.34133/bmr.0023 · Cited by 32
Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders
Arjunan, P., Kathirvelu, D., Mahalingam, G., Goel, A., Zacharaiah, U. G., Srivastava, A., & Marepally, S. K. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.015 · Cited by 33
Rapid generation of long, chemically modified pegRNAs for prime editing
Lei, X., Huang, A., Chen, D., Wang, X., Ji, R.-J., Wang, J., Zhang, Y., Zhang, Y., Lu, S., Zhang, K., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02394-x · Cited by 31
Self-citationDisruptive Technology: CRISPR/Cas-Based Tools and Approaches
Patsali, P., Kleanthous, M., & Lederer, C. W. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00391-4 · Cited by 31
Nanoparticle technologies: Recent state of the art and emerging opportunities
Parupudi, A., Mulagapati, S. H. R., & Subramony, J. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820757-4.00009-0 · Cited by 34
Engineered CRISPR Systems for Next Generation Gene Therapies
Pineda, M., Moghadam, F., Ebrahimkhani, M. R., & Kiani, S. (2017) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00011 · Cited by 30
Multi-targeting peptides for gene carriers with high transfection efficiency
Zhao, J., Li, Q., Hao, X., Ren, X., Guo, J., Feng, Y., & Shi, C. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb02012k · Cited by 30
Qiao, J., Li, W., Lin, S., Sun, W., Ma, L., & Liu, Y. (2019) · Communications Biology · doi:10.1038/s42003-019-0402-x · Cited by 30
Qiu, M., Glass, Z., & Xu, Q. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b00783 · Cited by 30
CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss
Farooq, R., Hussain, K., Tariq, M., Farooq, A., & Mustafa, M. (2020) · Journal of Applied Genetics · doi:10.1007/s13353-019-00535-6 · Cited by 30
The evolution and history of gene editing technologies
Randhawa, S., & Sengar, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.002 · Cited by 31
Targeting the Apoa1 locus for liver-directed gene therapy
Giorgi, M. D., Li, A., Hurley, A. E., Barzi, M., Doerfler, A. M., Cherayil, N. A., Smith, H. E., Brown, J. D., Lin, C. Y., Bissig, K., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.011 · Cited by 31
Smart Strategies for Precise Delivery of CRISPR/Cas9 in Genome Editing
Hasanzadeh, A., Noori, H., Jahandideh, A., Moghaddam, N. H., Mousavi, S. M. K., Nourizadeh, H., Saeedi, S., Karimi, M., & Hamblin, M. R. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01112 · Cited by 30
Ohno, H., Akamine, S., Mochizuki, M., Hayashi, K., Akichika, S., Suzuki, T., & Saito, H. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad019 · Cited by 31
CRISPR-Mediated Modification of DNA Methylation Pattern in the New Era of cancer therapy
Maroufi, F., Maali, A., Abdollahpour‐Alitappeh, M., Ahmadi, M. H., & Azad, M. (2020) · Epigenomics · doi:10.2217/epi-2020-0110 · Cited by 29
Polyethylenimine-Functionalized Carbon Dots for Delivery of CRISPR/Cas9 Complexes
Hashemzadeh, I., Hasanzadeh, A., Radmanesh, F., Chegeni, B. K., Hosseini, E. S., Kiani, J., Shahbazi, A., Naseri, M., Fatahi, Y., Nourizadeh, H., et al. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00890 · Cited by 29
Yadav, M., Atala, A., & Lu, B. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.04.114 · Cited by 29
Clinical progress in genome-editing technology and in vivo delivery techniques
Khirallah, J., Eimbinder, M., Li, Y., & Xu, Q. (2023) · Trends in Genetics · doi:10.1016/j.tig.2022.12.001 · Cited by 31
Self-citationCorrection of a urea cycle defect after ex vivo gene editing of human hepatocytes
Zabulica, M., Srinivasan, R. C., Akçakaya, P., Allegri, G., Bestas, B., Firth, M. A., Hammarstedt, C., Jakobsson, T., Jakobsson, T., Ellis, E. C. S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.024 · Cited by 29
CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy
Zhang, X., Wang, L., Liu, M., & Li, D. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9057-2 · Cited by 28
New Technologies To Enhance In Vivo Reprogramming for Regenerative Medicine
Larouche, J. A., & Aguilar, C. A. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.11.003 · Cited by 28
Ginocchio, V. M., Ferla, R., Auricchio, A., & Brunetti‐Pierri, N. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.151 · Cited by 29
Hwang, J., & Yokota, T. (2019) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2019.5 · Cited by 29
Versatile enzymology and heterogeneous phenotypes in cobalamin complementation type C disease
Esser, A. J., Mukherjee, S., Dereven’kov, I. А., Makarov, S. V., Jacobsen, D. W., Spiekerkoetter, U., & Hannibal, L. (2022) · iScience · doi:10.1016/j.isci.2022.104981 · Cited by 28
Cho, H., Yoo, M., Pongkulapa, T., Rabie, H., Muotri, A. R., Yin, P. T., Choi, J., & Lee, K. (2024) · Advanced Science · doi:10.1002/advs.202306432 · Cited by 29
CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders
Hussen, B. M., Najmadden, Z. B., Abdullah, S. R., Rasul, M. F., Mustafa, S. A., Ghafouri‐Fard, S., & Taheri, M. N. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01713-8 · Cited by 28
Intelligent Design of Lipid Nanoparticles for Enhanced Gene Therapeutics
Yuan, Y., Li, Y., Li, G., Lei, L., Huang, X., Li, M., & Yao, Y. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00925 · Cited by 28
Self-citationThe Yin and Yang of nucleic acid-based therapy in the brain
Gustincich, S., Zucchelli, S., & Mallamaci, A. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.11.001 · Cited by 27
Advancements in Nanomedicine for Multiple Myeloma
Detappe, A., Bustoros, M. W., Mouhieddine, T. H., & Ghoroghchian, P. P. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.04.005 · Cited by 27
Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing
Xu, Y., Liu, R., & Dai, Z. (2020) · Nanoscale · doi:10.1039/d0nr05452f · Cited by 27
Engineering guide RNA to reduce the off-target effects of CRISPR
Wu, J., & Yin, H. (2019) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.11.003 · Cited by 28
Self-citationBioresponsive polyplexes – chemically programmed for nucleic acid delivery
Hager, S., & Wagner, E. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1526922 · Cited by 26
Huang, J. Y., Kan, S., Sandfeld, E. K., Dalton, N. D., Rangel, A. D., Chan, Y., Davis‐Turak, J., Neumann, J. C., & Wang, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-65259-8 · Cited by 26
Aljanahi, A. A., Lazzarotto, C. R., Chen, S., Shin, T., Cordes, S., Fan, X., Jabara, I., Zhou, Y., Young, D. J., Lee, B., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.016 · Cited by 27
Self-citationGenome Editing for the Study of Cardiovascular Diseases
Chadwick, A. C., & Musunuru, K. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0830-5 · Cited by 28
Luan, X., Chen, X., Tang, Y., Zhang, J., Gao, X., Ke, H., Lin, Z., & Zhang, X. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.005 · Cited by 28
Advances in understanding disease mechanisms and potential treatments for Crigler–Najjar syndrome
Bortolussi, G., & Muro, A. F. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1495558 · Cited by 27
Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease
Baker, C. M., & Hayden, M. S. (2020) · F1000Research · doi:10.12688/f1000research.23185.1 · Cited by 26
Kohama, Y., Higo, S., Masumura, Y., Shiba, M., Kondo, T., Ishizu, T., Higo, T., Nakamura, S., Kameda, S., Tabata, T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72216-y · Cited by 25
Salekdeh, P. R., Ma’mani, L., Tavakkoly‐Bazzaz, J., Mousavi, H., Modarressi, M. H., & Salekdeh, G. H. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00838-z · Cited by 26
Potential Use of CRISPR/Cas13 Machinery in Understanding Virus–Host Interaction
Bayoumi, M. M., & Munir, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.743580 · Cited by 26
Gene editing innovations and their applications in cardiomyopathy research
Kyriakopoulou, E., Monnikhof, T., & van Rooij, E. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050088 · Cited by 26
CRISPR editing in biological and biomedical investigation
Huang, J., Wang, Y., & Zhao, J. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26141 · Cited by 25
Nasri, M., Mir, P., Dannenmann, B., Amend, D., Skroblyn, T., Xu, Y., Schulze‐Osthoff, K., Klimiankou, M., Welte, K., & Skokowa, J. (2019) · Blood Advances · doi:10.1182/bloodadvances.2017015511 · Cited by 25
Lipid and polymer mediated CRISPR/Cas9 gene editing
Gong, Y., Tian, S., Yang, X., & Zhang, S. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00207k · Cited by 25
Liu, J., & Shui, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.014 · Cited by 24
Jiang, W., Liu, L., Chang, Q., Xing, F., Ma, Z., Fang, Z., Zhou, J., Fu, L., Huiyang, W., Huang, X., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19774-4 · Cited by 24
Self-citationBae, T., Hur, J. W., Kim, D., & Hur, J. K. (2019) · Genes & Genomics · doi:10.1007/s13258-019-00830-w · Cited by 26
Induced Liver Regeneration Enhances CRISPR/Cas9-Mediated Gene Repair in Tyrosinemia Type 1
Zhang, Q., Tiyaboonchai, A., Nygaard, S. C., Baradar, K., Major, A. M., Balaji, N., & Grompe, M. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.042 · Cited by 24
Hu, M., Cherkaoui, I., Misra, S., & Rutter, G. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.576632 · Cited by 24
CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases
Rasoulinejad, S. A., & Maroufi, F. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00345-4 · Cited by 24
Lisjak, M., Caneva, A. D., Marais, T., Barbon, E., Biferi, M. G., Porro, F., Barzel, A., Zentilin, L., Kay, M. A., Mingozzi, F., et al. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.785698 · Cited by 24
In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria
Martínez-Turrillas, R., Martín-Mallo, Á., Rodríguez-Diaz, S., Zapata‐Linares, N., Rodríguez-Márquez, P., Martín‐Úriz, P. S., Vilas‐Zornoza, A., Calleja-Cervantes, M. E., SALIDO, E. C., Prósper, F., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.006 · Cited by 25
Nonviral Delivery of CRISPR/Cas Systems in mRNA Format
Liu, Z., Li, Z., & Li, B. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200082 · Cited by 25
Therapeutic applications of CRISPR RNA-guided genome editing
Koo, T., & Kim, J. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw032 · Cited by 24
Therapeutic editing of hepatocyte genome in vivo
de Galarreta, M. R., & Lujambio, A. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.012 · Cited by 25
Yu, M., Ortega, C., Si, K., Molinaro, R., Schöen, F. J., Leitão, R. F. D. C., Xu, X., Mahmoudi, M., Ahn, S., Liu, J., et al. (2018) · Theranostics · doi:10.7150/thno.24365 · Cited by 24
Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli‐Responsive Vehicles
Cai, W., Luo, T., Mao, L., & Wang, M. (2020) · Angewandte Chemie · doi:10.1002/ange.202005644 · Cited by 25
In vivo gene therapy potentials of CRISPR-Cas9
Xue, H.-Y., Zhang, X., Wang, Y., Lu, X., Dai, W.-J., & Xu, Y. C. (2016) · Gene Therapy · doi:10.1038/gt.2016.25 · Cited by 24
Genome Editing in Neurosciences
Jaenisch, R., Gage, F. H., & Zhang, F. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2 · Cited by 23
Therapeutic application of the CRISPR system: current issues and new prospects
Lee, M., & Kim, S. (2019) · Human Genetics · doi:10.1007/s00439-019-02028-2 · Cited by 23
Nuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver.
Te, B., Anglin, C. M., Bridges, P. H., & Cottle, R. N. (2017) · PubMed Central · Cited by 24
López‐Márquez, A., Morin, M., Fernández-Peñalver, S., Badosa, C., Hernández-Delgado, A., Benito, D. N., Ortez, C., Nascimento, A., Grinberg, D., Balcells, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084410 · Cited by 23
In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia
Lee, J. H., & Han, J. P. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00705-1 · Cited by 24
Steffin, D., Hsieh, E. M., & Rouce, R. H. (2019) · Advances in Pediatrics · doi:10.1016/j.yapd.2019.04.001 · Cited by 24
Kang, W., Zhao, X., Sun, Z., Dong, T., Jin, C., Tong, L., Zhu, W., Tao, Y., & Wu, H. (2020) · Gene Therapy · doi:10.1038/s41434-020-0124-1 · Cited by 23
Smith, J. L., Rodríguez, T., Mou, H., Kwan, S., Pratt, H., Zhang, X., Cao, Y., Liang, S., Özata, D. M., Yu, T., et al. (2020) · Hepatology · doi:10.1002/hep.31389 · Cited by 23
Self-citation
Metadata
- Authors
- Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., Gupta, A., Bolukbasi, M. F., Walsh, S., Bogorad, R. L., Gao, G., Weng, Z., Dong, Y., Koteliansky, V., Wolfe, S. A., Langer, R., Xue, W., & Anderson, D. G.
- Affiliations
- Koch Institute for Integrative Cancer Research At MIT (US)
- University of Massachusetts Chan Medical School (US)
- Tongji University (CN)
- The Ohio State University (US)
- Skolkovo Institute of Science and Technology (RU)
- Harvard–MIT Division of Health Sciences and Technology (US)
- Corresponding author
- Xue, Wen
- Anderson, Daniel G
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2016-02-01
- Volume
- 34
- Issue
- 3
- Pages
- 328-333
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC5423356
- OpenAlex
- W2260024370
- Cited by
- 876
- References
- 47
- Citations by year
- 2026: 26 · 2025: 56 · 2024: 44 · 2023: 52 · 2022: 90 · 2021: 108 · 2020: 110 · 2019: 104 · 2018: 128 · 2017: 112 · 2016: 46
- FWCI
- 67.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- eScholarship@UMassChan (submittedVersion)
- Funders
- National Institutes of Health (1f32eb017625-01)
- National Eye Institute (P30EY012196)
- National Cancer Institute (5‑U54‑CA151884‑04, U54CA151884, R00CA169512, P30CA014051, P30-CA-14051)
- National Institute of Biomedical Imaging and Bioengineering (1F32EB017625, F32 EB017625)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- therapeutic genome editing, CRISPR/Cas9, lipid nanoparticle delivery, adeno-associated virus vectors, hereditary tyrosinemia, fumarylacetoacetate hydrolase
- MeSH terms
- Animals, Disease Models, Animal, Genetic Vectors, Humans, Lipids, Mutation, Viruses, Genome, Human, RNA Editing, Gene Transfer Techniques, Tyrosinemias, Mice, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
